β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice

Blood

Volumn 109, Issue 4, 2007, Pages 1687-1691

  Kim, Andrew ^a   Morgan, Kelly ^b   Hasz, Diane E ^b   Wiesner, Stephen M ^b   Lauchle, Jennifer O ^a   Geurts, Jennifer L ^b   Diers, Miechaleen D ^b   Le, Doan T ^a   Kogan, Scott C ^a,c   Parada, Luis F ^d   Shannon, Kevin ^a,c   Largaespada, David A ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e 6 160 Jackson Hall   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR BETA; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; FETUS; GENE MUTATION; HEMATOPOIETIC STEM CELL; LIVER CELL; MOUSE; MYELOPROLIFERATIVE DISORDER; NEUROFIBROMATOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR SUPPRESSOR GENE;

EID: 33846902274     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-025395     Document Type: Article

References (25)

1. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol. 1981;29:33-56.
2. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today. 1996;2:468-475.
3. Arceci RJ, Longley BJ, Emanuel PD. Atypical cellular disorders. Hematology (Am Soc Hematol Educ Program). 2002:297-314.
4. Xu G, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599-608.
5. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69:265-273.
6. Parada LF. Neurofibromatosis type 1. Biochim Biophys Acta. 2000;1471:M13-M19.
7. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumor predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7:353-361.
8. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Devel. 1994;8:1019-1029.
9. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12:137-143.
10. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148.
11. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103:4243-4250.
12. Nicola NA, Smith A, Robb L, Metcalf D, Begley CG. The structural basis of the biological actions of the GM-CSF receptor. Ciba Found Symp. 1997;204:19-27; discussion 27-32.
13. Okuda K, Foster R, Griffin JD. Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann N Y Acad Sci. 1999;872:305-312; discussion 312-313.
14. Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity. 1995;2:211-222.
15. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073-1083.
16. Zhu Y, Romero MI, Ghosh P, et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001;15:859-876.
17. Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest. 2001;108:709-715.
18. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195.
19. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12:137-143.
20. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 1998;187:1893-1902.
21. Katsumoto TR, Duda J, Kim A, et al. Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. J Exp Med. 2005;201:853-858.
22. Woodcock JM, McClure BJ, Stomski FC, Elliott MJ, Bagley CJ, Lopez AF. The human granulocyte-macrophage colony-stimulating factor (GMCSF) receptor exists as a preformed receptor complex that can be activated by GM-CSF, interleukin-3, or interleukin-5. Blood. 1997;90:3005-3017.
23. Iversen PO, Lewis ID, Turczynowicz S, et al. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood. 1997;90:4910-4917.
24. Iversen PO, Rodwell RL, Pitcher L, Taylor KM, Lopez AF. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood. 1996;88:2634-2639.
25. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920-922.